TTR and polyneuropathy: Alternative treatments for TTR, the TTR silencers patisiran [10] and inotersen [9] received regulatory approval for hereditary ATTR polyneuropathy in late 2010s and are undergoing clinical trials for ATTR cardiomyopathy.